Patients With CML Continue to Be Prescribed Costly Second-Gen TKIs
Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.
Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.